Tenofovir Alafenamide CAS 379270-37-8

Product Description:

Product Name: Tenofovir alafenamide CAS NO: 379270-37-8

Synonyms:

propan-2-yl(2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate;

Tenofovir alafenamide free base;

Sp-Tenofovir-phosphonamidate,phenyl,L-alanine isopropyl ester;

Chemical & Physical Properties:

Appearance: White to off-white solid powder

Assay :≥99.0%

Density: 1.39±0.1 g/cm3 (Predicted)

Boiling Point: 640.4±65.0℃(Predicted)

Flash Point: 341.1±34.3℃

PKa: 4.21±0.10 (Predicted)

Vapor Pressure: 0.0±1.9 mmHg at 25℃

Index of Refraction: 1.630

Water Solubility: Practically insoluble (0.04 g/L) (25℃)

Tenofovir alafenamide (INN/USAN, formerly GS-7340) is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It was developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent.Gilead announced a phase 3 clinical trial evaluating a single-tablet regimen combining tenofovir alafenamide with cobicistat, emtricitabine and elvitegravir and developed a coformulation of the drug with cobicistat, emtricitabine and the protease inhibitor darunavir. In a 48 week study comparing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (trade name Genvoya), the results showed the newer drug to be noninferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function. The FDA approved the TAF-based treatment regimen for treatment of HIV-1 in November 2015. Genvoya is the first TAF-based regimen to receive approval.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.